학술논문

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
Document Type
Article
Source
In The Lancet Oncology May 2023 24(5):483-495
Subject
Primary Research
Articles
Language
ISSN
1470-2045